ArticleProbiotics and antimicrobial proteins2026
Exploring the Probiotic Potential and Immunomodulatory Capacity of Lactococcus lactis NCDO 2118 Against Bacterial Pathogens and Trypanosoma cruzi.
Article in Probiotics and antimicrobial proteins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Postbiotic GABA and Lactobacillus plantarum 1-2-3 Alleviate Corticosterone-induced Abdominal Fat Deposition in Laying Hens by Suppressing Adipogenesis and Enhancing Lipolysis.Probiotics and antimicrobial proteins · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Probiotic microorganisms capable of modulating the immune response and exerting antimicrobial activity represent promising tools in host-pathogen control. This study aimed to evaluate the probiotic potential and immunomodulatory capacity of Lactococcus lactis NCDO 2118 (L. lactis NCDO 2118) and the cell-free supernatant (CFS) against pathogenic bacteria and Trypanosoma cruzi (T. cruzi). We assessed acid and bile salt resistance, adhesion to abiotic surfaces, inhibition of bacterial growth, cytotoxicity, and immunomodulatory activity in vitro using RAW 264.7, THP-1, and BMDC cell lines. In vivo, C57BL/6 mice were treated orally to investigate systemic immunomodulatory responses. The strain exhibited tolerance to pH 3.5 and 0.3% bile salts, also showed adhesion capacity on polystyrene surface, and inhibited the growth of Escherichia coli, Staphylococcus aureus, Enterococcus faecalis, Enterococcus faecium, and Enterococcus gallinarum. Neither the bacterium nor its CFS exhibited cytotoxic effects. In vitro, assays showed modulation of cytokine production, especially increased IL-10 in BMDCs (bone marrow-derived dendritic cells) and reduced IL-4 in T. cruzi-infected macrophages, while in vivo assays revealed increased IL-10 levels in spleens and TNF-α in livers of treated mice. These findings highlight L. lactis NCDO 2118 as a promising probiotic candidate with dual antimicrobial and immunomodulatory actions. To our knowledge, this is the first study to demonstrate the ability of L. lactis NCDO 2118 to modulate cytokine profiles and antiparasitic responses relevant to Chagas disease.
Indexed as
Identifiers
41299141What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.